Navigation Links
JCI table of contents: Aug. 16, 2007
Date:8/16/2007

formation in the eye led the authors to suggest that inhibiting S1P2R activation in the retina might provide a new therapeutic approach to treating diseases of the eye caused by the presence of an abnormal blood vessel network.

TITLE: Essential role of sphingosine 1–phosphate receptor 2 in pathological angiogenesis of the mouse retina

AUTHOR CONTACT: Timothy Hla University of Connecticut School of Medicine, Farmington, Connecticut, USA. Phone: (860) 679-4128; Fax: (860) 679-1201; E-mail: hla@nso2.uchc.edu.

Christopher DeFrancesco Office of Communications University of Connecticut Health Center, Farmington, Connecticut, USA. Phone: 860-679-3914; E-mail: cdefrancesco@uchc.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=31123


ONCOLOGY: A winning combination for the treatment of cancer

The immune system does not destroy tumors even though they express molecules that should activate immune cells. The immune system is therefore said to be tolerant of the tumors. Several molecules and cell types have been implicated in the induction of immune system tolerance to tumors, including, in mice, a small population of immune cells known as plasmacytoid dendritic cells (pDCs) that produce the enzyme indoleamine 2,3-dioxygenase (IDO) and that are isolated from the lymph nodes that drain the site of the tumor. Now, researchers from the Medical College of Georgia, Augusta, have identified how these mouse IDO-expressing pDCs induce tumor-specific immune tolerance.

In the study, which appears online on August 16 in advance of publication in the September print issue of the Journal of Clinical Investigation, David Munn and colleagues found that mouse IDO-expressing pDCs from tumor-draining lymph nodes directly activate the suppressive f
'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology news :

1. Highly adaptable genome in gut bacterium key to intestinal health
2. Development of portable infectious disease detector
3. Scientists identify genes responsible for black rot disease in vegetables
4. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
5. Aloe vera coating may prolong freshness, safety of fruits and vegetables
6. Nanotechnology to provide portable genetic risk detection
7. New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate
8. Implantable pumps extend lives of patients too sick for transplant
9. Bioengineers create stable networks of blood vessels
10. Portable cocaine sensor developed at UC Santa Barbara
11. Researchers develop portable vein finder for faster, more accurate injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... vibrant insects, with colorations sometimes designed to deflect predators. ... defenses may be driven by enemies one-tenth their size. ... researchers have believed large predators like birds mainly influenced ... behavioral study to directly test the defense mechanism of ...
... be it heat or electricity, has to be used right ... its transportation can be rather complicated. Creating solar cells capable ... that is to say fuel, is therefore the future challenge ... are working on a catalyst that imitates and improves what ...
... amino acids in order to conduct electricity, according to a ... open-access journal of the American Society for Microbiology, on Tuesday, ... sulfurreducens uses these nanowires, called pili, to transport electrons ... of these wires can also be harnessed by humans for ...
Cached Biology News:UF study shows spiders, not birds, may drive evolution of some butterflies 2UF study shows spiders, not birds, may drive evolution of some butterflies 3Catalysts that produce 'green' fuel 2Biological wires carry electricity thanks to special amino acids 2
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/30/2015)... ... ... of its 2015 growth plan and as a follow up to the recently announced expansion ... is pleased to announce that it has begun construction on a new Microbiological Laboratory. The ... strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
(Date:7/29/2015)... , July 30, 2015 According to ... - Growth, Trends & Forecasts (2015-2020), , published by Mordor ... 30.25 billion by the end of 2020, with ... for more than 40% of the global market size. The ... a CAGR of 13.7% during the period of (2015-2020). ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... June 11 MedNet Solutions, a global life sciences ... will unveil a variety of exciting new and enhanced ... Annual Meeting, June 22-24, 2009, in San Diego, CA. ... its market-leading electronic data capture/eClinical tool set to improve ...
... ... how Earned Value Management can improve control over clinical development costs, payments, and accruals ... , ... (PRWEB) June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical ...
... (Nasdaq: MDVN ) today ... CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial ... Alzheimer,s disease. , , The international, double-blind, ... the enrollment target of 525 patients. More than 40 ...
Cached Biology Technology:MedNet Solutions to Introduce New EDC/eClinical Technologies at the 2009 Drug Information Association Annual Meeting 2ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 3Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 4
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Biology Products: